Company intelligence / Profile preview
Sagimet Biosciences
- Ownership
- Public · SGMT
- Employees
- ~50
- Development stage
- Other
Overview
Sagimet Biosciences has demonstrated positive results in Phase 2 trials for its lead candidate denifanstat in MASH, with the FASCINATE‑1 and FASCINATE‑2 studies showing good tolerability and efficacy. Denifanstat received FDA Breakthrough Therapy Designation for MASH based on these results. The company has initiated or plans to initiate multiple Phase 3 trials for denifanstat in both MASH and acne. Additional programs are advancing toward IND-enabling or early clinical stages[1][10].
- Therapeutic areas
- OncologyDermatologyMetabolic Disorders
- Modalities
- Small molecules (Fatty Acid Synthase [FASN] inhibitors)
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $297.1M
- Total revenue
- $0
- Enterprise value
- $59M
Beyond the preview
Go deeper on Sagimet Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sagimet Biosciences.